Table 2.
Progression with age (slope of regression) assessed by linear mixed-effect model analysis (LMM) in 152 patients with cystic fibrosis, evaluated over an age-range of 6 to 18 years.
| Progression with age of lung function | 95% confidence interval | Age as fixed effect | |||
| lower | upper | F-value | Significance | ||
| FRCpleth | 0.142 | 0.126 | 0.158 | 298.3 | 0.0001 |
| FRCMBNW | -0.062 | -0.081 | -0.043 | 42.1 | 0.001 |
| LCI | 0.240 | 0.204 | 0.276 | 174.4 | 0.0001 |
| VTG | 0.180 | 0.160 | 0.200 | 320.9 | 0.0001 |
| sReff | 0.373 | 0.319 | 0.427 | 182.1 | 0.0001 |
| FVC | 0.005 | -0.023 | 0.033 | 0.1 | n.s. |
| FEV1 | -0.177 | -0.206 | -0.148 | 139.6 | 0.0001 |
| FEF50 | -0.474 | -0.527 | -0.420 | 304.0 | 0.0001 |